Clinical trials
DLBCL clinical trials
Below are recruiting dlbcl clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04512716RecruitingEarly Phase 1
Radioimmunotherapy then CD19 CAR T for hard-to-treat blood cancers
This early-phase study tests a two-step treatment: first a targeted radioactive antibody (131-I apamistamab) and then CD19 CAR T-cell therapy. It is for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or diffuse large B-cell lymphoma (DLBCL) that is not responding or has come back, aiming to shrink cancer using engineered immune cells.
Basking Ridge, New JerseyAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Birmingham, AlabamaAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT04432714RecruitingPhase 1/Phase 2
Lenalidomide plus R-DA-EPOCH for MYC-rearranged lymphoma
This early-phase study tests whether lenalidomide combined with R-DA-EPOCH can treat untreated diffuse large B-cell lymphoma (DLBCL) that has a MYC rearrangement. It may help control the lymphoma, but it’s also designed to find the safest and most effective dosing.
Nanjing, JiangsuAges 18–60 - NCT05552937RecruitingPhase 2
Tafasitamab plus lenalidomide for relapsed large B-cell lymphoma
This trial studies whether the combination of tafasitamab and lenalidomide can work better and be safe for people whose large B-cell lymphoma has returned or did not respond. It may help by targeting lymphoma cells and supporting immune activity, while monitoring side effects closely.
Hangzhou, ZhejiangAges 18 years+ - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+ - NCT07778212Recruiting
New drug combo for aggressive lymphoma
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
Xiamen, FujianAges 18 years+ - NCT07749365RecruitingPhase 2
Combination therapy for newly diagnosed brain lymphoma
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
Xiamen, FujianAges 18 years+ - NCT06647940RecruitingPhase 2
Orelabrutinib plus R-CHOP for CD5-positive DLBCL
This trial tests whether adding a targeted therapy called orelabrutinib to standard chemotherapy (R-CHOP) helps people with a specific type of fast-growing lymphoma (CD5-positive DLBCL). If you have this lymphoma and haven't had a BTK inhibitor before, this combination might work better than chemo alone.
Guangzhou, ChinaAges 18 years+ - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT06026488Recruiting
Study of DLBCL by genetic subtype
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07397832RecruitingPhase 2
CRP drug combo for older adults with untreated double-positive DLBCL
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT06151080RecruitingPhase 2
Lenalidomide plus G-CHOP for new DLBCL with follicular lymphoma
This study tests combining the drug lenalidomide with a standard chemotherapy regimen (G-CHOP) for people newly diagnosed with a specific type of lymphoma that has both aggressive and slow-growing parts. The goal is to see if this combination works better than standard treatment alone.
Xiamen, FujianAges 18–70 - NCT06158399RecruitingPhase 2
Combination therapy for a specific type of lymphoma
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
Xiamen, FujianAges 18–70 - NCT06779435Recruiting
Tucidinostat-based treatment for untreated DLBCL
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07288879RecruitingPhase 2
CAR T-cell therapy for relapsed or refractory DLBCL
This trial tests a new CAR T-cell therapy called MB-CART2019.1 for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The therapy uses your own immune cells to fight the cancer.
TokyoAges 18 years+ - NCT06758037RecruitingPhase 2
HiR Plus X therapy for elderly DLBCL patients who can't have chemo
This study tests a new treatment called HiR+X for older adults with a type of lymphoma (DLBCL) who cannot tolerate standard chemotherapy. It aims to offer a gentler but effective option.
Ningbo, ZhejiangAges 70–100 - NCT07255963RecruitingPhase 2
Pirtobrutinib, Lisaftoclax, and Rituximab for relapsed DLBCL
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Suzhou, JiangsuAges 18 years+
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
DLBCL trials by city
Studies with a site in or near these metro areas.
DLBCL trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for dlbcl?
- Yes. Clin2 currently lists 151 recruiting dlbcl studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dlbcl trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dlbcl trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.